GSK stock gains on Berenberg upgrade and pipeline confidence
Published on 09/20/2026 at 18:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
GSK plc stock (ISIN GB0009252882) is trading under the impression of a fresh analyst upgrade, after Berenberg raised its view on the London-listed drugmaker to Buy and lifted the price target from GBP 20 to GBP 22 on September 20, 2026, citing stronger pipeline momentum and recent business development activity that support the long-term growth outlook.
Analyst upgrade supports valuation
According to Sharecast on September 20, 2026, analysts at Berenberg upgraded GSK from Hold to Buy and increased their target price on the stock from GBP 20 to GBP 22, arguing that recent business-development deals and visible pipeline progress have strengthened the company’s long-term growth profile and left the valuation discount versus peers looking excessive.
The move from a Hold to a Buy stance, together with a 10 percent uplift in the target price from GBP 20 to GBP 22, gives investors a clearer quantified signal that at least one major brokerage now sees more upside in GSK shares relative to previous expectations, and explicitly ties that view to the company’s R&D assets and external deal-making rather than purely short-term cost measures.
Earnings and dividend backdrop
As reported by Europa Press on September 20, 2026, GSK has doubled its profit up to September, reaching EUR 5,768 million over the period, and has improved its forecasts while continuing to distribute dividends, which underlines that the operating performance and shareholder returns are both moving in a supportive direction.
The profit figure of EUR 5,768 million for the period up to September represents a 100 percent increase compared with the prior-year level, highlighting that profitability has expanded markedly alongside an improved guidance framework, even though the exact quarter or fiscal-year designation of the results is not fully detailed in the snippet and therefore is best treated as a strong historical comparison rather than the sole current snapshot.
Stock position and investor view
Per the latest overview of large United Kingdom stocks, GSK plc is listed with a share price of USD 50.22 and a market capitalization of USD 100.62 billion, classed in the healthcare sector and headquartered in the UK, which places the company among the top tier of European pharma groups by size and indicates that the Berenberg target of GBP 22 leaves room relative to the current translated valuation level in US dollars.StockMarketRanks
The same ranking shows GSK’s market capitalization at approximately USD 100.62 billion as of September 20, 2026, with the shares down 1.65 percent on the day at USD 50.22, which gives a concrete sense of how the stock trades around the time of the Berenberg upgrade and how much scale the company brings to the global healthcare sector.StockMarketRanks
GSK stock price and market data
At the latest data point available for September 20, 2026, GSK stock is quoted at USD 50.22, corresponding to its listing in the United States context, with the price showing a 1.65 percent decline compared with the prior close, and the company’s market capitalization standing at USD 100.62 billion; this positions the share below the raised Berenberg target of GBP 22, suggesting potential upside in local-currency terms depending on exchange rates.StockMarketRanks
GSK stock profile
- Company: GSK plc
- ISIN: GB0009252882
- Ticker: GSK
- Trading venue: London Stock Exchange
- Price (as of September 20, 2026, 14:39): 50.22 USD
- Market capitalization: 100.62 billion USD (as of September 20, 2026)
- Sector / Industry: Healthcare / Pharmaceuticals
- Index membership: FTSE 100
